Duration of ICI may instead serve as a pragmatic, post-hoc indicator of clinical benefit that integrates multiple factors—including tumor biology, host immune response, and treatment tolerance—that are not captured by PD-L1 expression alone. Here, CD274 is linked to neoplasm.